Patents by Inventor Guy NIMROD
Guy NIMROD has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240101675Abstract: Described herein are method of generating and uses of polypeptides with dual binding specificity, wherein the polypeptides contain a first binding-site for a first antigen and a second binding-site for a second antigen. The second binding-site comprises amino acid variants of native amino acid sequences of polypeptides that bind to the first antigen, wherein the variants do not abrogate binding to said first antigen. In one embodiment, polypeptides with dual binding specificity to PD1 and OX40 are disclosed herein. In another embodiment, polypeptides with dual binding specificity to PD1 and GITR are disclosed herein.Type: ApplicationFiled: January 20, 2022Publication date: March 28, 2024Applicant: Biolojic Design Ltd.Inventors: ALIK DEMISHTEIN, Dotan OMER, Schmuel BERNSTEIN, ltay LEVIN, Yehezkel SASSON, Marek STRAJBL, Sharon FISCHMAN, Guy NIMROD, Michael ZEHNIN, Reut Barak FUCHS, Olga BLUVSHTEIN YERMOLAEV, Yair FASTMAN, Oshrat Shir TWITO, Yanay OFRAN
-
Publication number: 20240092888Abstract: Described herein are engineered anti-IL-2 antibodies with modified amino acid sequences. The engineered antibodies would confer modified receptor binding specificity to an IL-2-anti-IL2 antibody complex, inhibiting the binding of IL-2 to CD25. The engineered anti-IL-2 antibodies would facilitate expansion of subsets of effector immune cells and decrease undesirable effects caused by IL-2. Thus, the engineered anti-IL-2 antibodies would be useful in treating disease such as cancer and infection.Type: ApplicationFiled: October 23, 2023Publication date: March 21, 2024Applicant: Aulos Bioscience, IncInventors: Inbar AMIT, Itay LEVIN, Guy NIMROD, Sharon FISCHMAN, Reut BARAK FUCHS, Marek STRAJBL, Timothy WYANT, Michael ZHENIN, Olga BLUVSHTEIN YERMOLAEV, Yehezkel SASSON, Noam GROSSMAN, Natalia LEVITIN, Yanay OFRAN
-
Publication number: 20240059769Abstract: Described herein are engineered dual binding antibodies that bind to IL-13 and TSLP and uses thereof. Uses include treating allergic and respiratory conditions. Described herein are also libraries comprising the engineered dual binding antibodies, and methods of producing the engineered dual binding antibodies and functional and biochemical characterization of the antibodies.Type: ApplicationFiled: September 27, 2023Publication date: February 22, 2024Applicant: Biolojic Design Ltd.Inventors: ALIK DEMISHTEIN, Shmuel BERNSTEIN, Tomer SHLAMKOVICH, Ayelet CHEN, Yehezkel SASSON, Marek STRAJBL, Itay LEVIN, Sharon FISCHMAN, Yanay OFRAN, Guy NIMROD, Alexey SHNYDER, Hadar GATTEGNO, Nikol MALCHENKO, Olga BLUVSHTEIN YERMOLAEV, Noam GROSSMAN, Liron DANIELPUR, Itzhak MEIR, Morya IFRACH, Reut BARAK FUCHS, Michael ZHENIN
-
Patent number: 11851485Abstract: Described herein are engineered anti-IL-2 antibodies with modified amino acid sequences. The engineered antibodies would confer modified receptor binding specificity to an IL-2-anti-IL2 antibody complex, inhibiting the binding of IL-2 to CD25. The engineered anti-IL-2 antibodies would facilitate expansion of subsets of effector immune cells and decrease undesirable effects caused by IL-2. Thus, the engineered anti-IL-2 antibodies would be useful in treating disease such as cancer and infection.Type: GrantFiled: November 16, 2022Date of Patent: December 26, 2023Assignee: AULOS BIOSCIENCE, INC.Inventors: Inbar Amit, Itay Levin, Guy Nimrod, Sharon Fischman, Reut Barak Fuchs, Marek Strajbl, Timothy Wyant, Michael Zhenin, Olga Bluvshtein Yermolaev, Yehezkel Sasson, Noam Grossman, Natalia Levitin, Yanay Ofran
-
Publication number: 20230203152Abstract: Described herein are engineered anti-IL-2 antibodies with modified amino acid sequences. The engineered antibodies would confer modified receptor binding specificity to an IL-2-anti-IL2 antibody complex, inhibiting the binding of IL-2 to CD25. The engineered anti-IL-2 antibodies would facilitate expansion of subsets of effector immune cells and decrease undesirable effects caused by IL-2. Thus, the engineered anti-IL-2 antibodies would be useful in treating disease such as cancer and infection.Type: ApplicationFiled: November 16, 2022Publication date: June 29, 2023Applicant: Aulos Bioscience, IncInventors: Inbar AMIT, Itay LEVIN, Guy NIMROD, Sharon FISCHMAN, Reut BARAK FUCHS, Marek STRAJBL, Timothy WYANT, Michael ZHENIN, Olga BLUVSHTEIN YERMOLAEV, Yehezkel SASSON, Noam GROSSMAN, Natalia LEVITIN, Yanay OFRAN
-
Publication number: 20230167188Abstract: The present disclosure describes a number of anti-TNFR2 (tumor necrosis factor receptor 2) antibodies. These antibodies are TNFR2 agonists. In certain cases, these antibodies agonize TNFR2 in an Fc independent manner. These antibodies can modulate the proliferation and/or functions of regulatory T cells and myeloid-derived suppressor cells. In certain instances, these antibodies can be used to treat diseases such as GvHD or autoimmune diseases.Type: ApplicationFiled: July 1, 2021Publication date: June 1, 2023Applicant: Biolojic Design Ltd.Inventors: Inbar AMIT, Itay LEVIN, Ayelet CHEN, Tal VANA, Nino OREN, Dor SAMET, Efrat CHOEN ZADA, Natalia LEVITIN, Guy NIMROD, Yehezkel SASSON, Alik DEMISHTEIN, Timothy WYANT, Reut BARAK FUCHS, Yair FASTMAN, Sharon FISCHMAN, Marek STRAJBL, Michael ZHENIN, Olga BLUVSHTEIN YERMOLAEV, Noam GROSSMAN, Oshrat Shir TWITO, Nevet Zur BITON, Liron DANIELPUR, May Sofia BEN MAYOR, Yanay OFRAN
-
Publication number: 20230085471Abstract: Described herein are engineered anti-IL-2 antibodies with modified amino acid sequences. The engineered antibodies would confer modified receptor binding specificity to an IL-2-anti-IL2 antibody complex, inhibiting the binding of IL-2 to CD25. The engineered anti-IL-2 antibodies would facilitate expansion of subsets of effector immune cells and decrease undesirable effects caused by IL-2. Thus, the engineered anti-IL-2 antibodies would be useful in treating disease such as cancer and infection.Type: ApplicationFiled: February 15, 2021Publication date: March 16, 2023Applicant: Aulos Bioscience, IncInventors: Inbar AMIT, Itay LEVIN, Guy NIMROD, Sharon FISCHMAN, Reut BARAK FUCHS, Marek STRAJBL, Timothy WYANT, Michael ZHENIN, Olga BLUVSHTEIN YERMOLAEV, Yehezkel SASSON, Noam GROSSMAN, Natalia LEVITIN, Yanay OFRAN
-
Publication number: 20220415436Abstract: The present invention is directed to a method for generating a library of antigen binding molecules for screening for binding to an epitope of interest, said method comprising: a. selecting a template antigen-binding molecule from a set of possible template antigen binding molecules wherein said selected template does not specifically bind the epitope of interest but is known to specifically bind another epitope; b. selecting at least one residue position in said template antigen-binding molecule for mutation; and c. selecting at least one variant residue to substitute at the at least one residue position selected in b; such that a library containing a plurality of variants of said template is generated.Type: ApplicationFiled: August 11, 2022Publication date: December 29, 2022Applicant: Biolojic Design Ltd.Inventors: Yanay OFRAN, Guy NIMROD, Sharon FISCHMAN, Asael HERMAN
-
Patent number: 11468969Abstract: The present invention is directed to a method for generating a library of antigen binding molecules for screening for binding to an epitope of interest, said method comprising: a. selecting a template antigen-binding molecule from a set of possible template antigen binding molecules wherein said selected template does not specifically bind the epitope of interest but is known to specifically bind another epitope; b. selecting at least one residue position in said template antigen-binding molecule for mutation; and c. selecting at least one variant residue to substitute at the at least one residue position selected in b; such that a library containing a plurality of variants of said template is generated.Type: GrantFiled: November 25, 2015Date of Patent: October 11, 2022Assignee: Biolojic Design Ltd.Inventors: Yanay Ofran, Guy Nimrod, Sharon Fischman, Asael Herman
-
Publication number: 20180068055Abstract: The present invention is directed to a method for generating a library of antigen binding molecules for screening for binding to an epitope of interest, said method comprising: a. selecting a template antigen-binding molecule from a set of possible template antigen binding molecules wherein said selected template does not specifically bind the epitope of interest but is known to specifically bind another epitope; b. selecting at least one residue position in said template antigen-binding molecule for mutation; and c. selecting at least one variant residue to substitute at the at least one residue position selected in b; such that a library containing a plurality of variants of said template is generated.Type: ApplicationFiled: November 25, 2015Publication date: March 8, 2018Inventors: Yanay OFRAN, Guy NIMROD, Sharon FISCHMAN, Asael HERMAN